7

Lot Numbers

Somewhere in a filing cabinet that survived four decades and at least two congressional inquiries, there’s a government memo dated November 1, 1983, that reads less like a public health notice and more like a car recall. Cutter Laboratories is recalling 315 lots of Factor VIII and one lot of Factor IX. The lots have been traced to blood donations by an individual who died of AIDS the previous week. That individual made fifty paid donations at Austin Blood Components in Texas between November 1982 and September 1983. Fifty visits. One man. Three hundred and sixteen lots of medicine, manufactured from plasma pooled with thousands of other donors, already on shelves in hospitals from Tokyo to Toronto by the time anyone thought to check the paperwork.

This is where the plasma industry‘s own language gives away the whole story before a single word of criticism gets added to it. Lots. Not people. Lots, the way you’d track ball bearings or engine parts, because that’s structurally what a pooled plasma product is — thousands of individual human bodies, liquefied and mixed and numbered, the specific person who bled into batch 315 rendered permanently untraceable the moment his plasma met everyone else’s. The system wasn’t hiding the donors’ humanity as some kind of cover-up. It never had a slot for it in the first place. You cannot recall a lot number’s conscience.

What the Industry Called Sourcing

Start at the surface, because the surface is already grotesque enough to need no embellishment. Beginning in the mid-1960s, Arkansas ran a plasma collection operation out of the Cummins Unit state penitentiary, paying inmates for their blood the way a company might pay for scrap metal — cheap, steady, no questions the seller was in a position to refuse. By 1978, a private contractor called Health Management Associates had taken over both the prison’s medical care and its plasma program simultaneously, which is its own small masterpiece of conflict of interest: the same company deciding whether an inmate was healthy enough to bleed was also profiting from the answer being yes. Inmates reportedly bribed staff for what they called, with the gallows humor of people who understood exactly what was happening to them, “the right to bleed.” Nobody needed a whistleblower to explain the incentive structure. The incentive structure was the entire structure.

This wasn’t confined to prisons. Commercial plasma centers set up shop in poor urban neighborhoods, offering small cash payments to intravenous drug users and unhoused people — populations selected not despite their elevated risk of hepatitis and, eventually, HIV, but because their economic desperation made them reliably willing to show up twice a week and answer screening questions the way the check required them to answer, whatever the actual state of their health. Federal rules technically excluded donors with hepatitis histories. Enforcement was, by every honest historical account, close to theoretical.

Multiply one questionable donor across a pooling process that combined plasma from up to ten thousand people into a single batch of clotting-factor concentrate, and you have engineered, with real precision, the most efficient possible machine for turning one infected body into an international outbreak. Nobody designed the plasma industry to do this on purpose. They designed it to be cheap and scalable, and cheap-and-scalable turned out to have a body count nobody bothered to price in until the invoices started arriving in the form of dead hemophiliacs.

The Paper Trail Nobody Was Supposed to Find

By July of 1982, the CDC had already published its first report connecting AIDS to hemophilia patients. By December, a second report followed, along with an FDA warning that prison donors carried meaningfully elevated infection risk — a warning specific enough that several companies quietly stopped sourcing from prisons that same month. Arkansas’s contractor did not. It kept selling plasma to a Canadian broker, which kept distributing it internationally, because the warning was a suggestion and the contract was a revenue line, and revenue lines, historically, do not do very well in yielding to suggestions.

Then comes January 1983, and the document that turns institutional negligence into something a jury can actually hold a company accountable for. A Cutter Biological manager wrote, in language a company’s own lawyers would spend the next decade regretting, that there was “strong evidence to suggest that AIDS is passed on to other people through plasma products.” Later that same year, internal staff at the same company predicted what they themselves called a “gigantic epidemic” among hemophiliacs. Cutter kept selling its non-heat-treated concentrate in several markets anyway, because a competitor had already brought a safer, heat-treated version to market, and pulling the old product immediately would have meant admitting, out loud, in a press release, what the internal memo had already admitted in private.

Across the Atlantic, the euphemism reached a kind of dark poetry. Britain’s health minister in 1983, later giving evidence to the UK’s Infected Blood Inquiry decades on, admitted his department believed there was a “strong possibility” that blood products were transmitting AIDS — while telling the public, in an actual press release, that there was “no conclusive proof.” He would go on to defend that phrasing, under oath, as technically accurate. It is the kind of sentence that is legally defensible and morally worthless in exactly the same breath, and someone got paid a civil servant’s salary to construct it.

Negligence Has a Cousin, and Its Name Is Concealment

There’s a meaningful difference between a company reacting too slowly to bad news and a company actively working to make sure the bad news never reaches anyone in a position to act on it, and the plasma industry’s record contains documented instances of both — filed separately, because they are separate crimes even when they share a filing cabinet. The slow reaction is what Cutter’s January memo represents: real internal awareness, followed by a business decision to keep selling anyway while a safer product got developed. The concealment is something else. Internal correspondence from the period includes discussion, among Cutter’s own staff, of “giving the impression” of continuous safety improvement to the market — language chosen specifically to manage perception while the actual timeline for pulling the risky product lagged well behind what the company’s own scientists already understood. That is not a company failing to notice a problem fast enough. That is a company noticing the problem, understanding the coming reputational cost, and choosing to manage the cost instead of the harm.

Britain’s own inquiry, delivered in 2024 after forty-one years of survivors demanding it, went further than “slow reaction” as a verdict. It found a pattern of deliberate document destruction by officials and clinicians — records that should have existed and didn’t, an absence too consistent across too many departments to read as bureaucratic accident. You do not accidentally lose the paperwork that would prove you knew. You lose it on purpose, and you lose it because someone did the same cost-benefit calculation Cutter’s memo writers did, arrived at the same answer, and had the additional advantage of a government office’s authority to make the losing look procedural. This was never a single company’s failure of judgment. Baxter‘s Hyland division, Armour (Which began life as a meat-packing operation – go figure), Alpha Therapeutic, and France’s Institut Mérieux were all producing and exporting the same category of product, under the same pooling economics, into the same information environment — and the industry’s collective response to mounting evidence was not collective disclosure. It was, across multiple companies and at least one national government, a collective decision to manage the story for as long as the story could still be managed.

Who Got to Be a Customer, and Who Got to Be Supply

Somewhere in every plasma company’s org chart, there was a line separating the people whose blood went in from the people whose treatment came out, and that line mapped, with an accuracy too consistent to be coincidence, onto who had power and who didn’t. The donor pool skewed toward prisoners, addicts, and the desperately poor — populations already carrying every disadvantage a society knows how to inflict, now recruited specifically because that disadvantage made them cheap and compliant. The patient pool on the other end was, disproportionately, hemophiliacs: a population with a genetic condition they hadn’t chosen, dependent on a treatment they hadn’t invented, trusting a system that had already quietly decided their safety was worth less than a quarter’s earnings report.

Nobody in that supply chain thought of themselves as choosing which category of vulnerable person to sacrifice for which other category of vulnerable person. That’s not how the decision got made. It got made in the aggregate, in a spreadsheet, in the gap between what heat-treating the concentrate would cost and what a hemophiliac’s infection would cost the company in the specific, narrow sense that mattered to the people doing the math: legally, actuarially, this quarter. Both groups — the men bleeding for scrip in a Louisiana cellblock and the children waiting on a clotting factor that would let them survive a nosebleed — were, from the industry’s actual operating logic, inventory. One end of the supply chain. The other end of the demand curve. Neither one was ever, in the sense that would have changed a single purchasing decision, a person.

What the Inventory Model Cost, Counted Honestly

The tally, even in its most conservative telling, is not abstract. Somewhere between six and ten thousand American hemophiliacs contracted HIV through contaminated factor concentrate, with a considerably larger number infected with hepatitis C. Britain’s own reckoning, delivered in a final inquiry report in May of 2024 — forty-one years after the “no conclusive proof” press release — concluded that thousands of patients had been infected through blood and blood products the government had reason to suspect were dangerous well before it acted. Canada’s Krever Commission, convened in the 1990s, traced infections directly back to Arkansas prison plasma routed through brokers with names most patients never heard and would never have consented to trust. France halted imports. Japan, Germany, Ireland opened their own inquiries. Arkansas did not stop selling prisoner plasma until 1994 — the last state in the country to close a program that the FDA had flagged as dangerous a full twelve years earlier.

The facts don’t need decoration here. The arithmetic is clear: a single infected man’s fifty paid visits to a Texas plasma center produced 316 recalled lots of medicine, and that was one donor, out of thousands, in one country, across two decades of an industry that had been explicitly warned and kept operating anyway. The scandal was never the existence of a mistake. It was the volume of evidence a system was willing to absorb, and keep selling through, before it agreed to call the mistake by its name.

What the Word “Harvesting” Was Always Going to Cost Us

There’s a reason the phrase that stuck to this whole episode was “blood harvesting” and not something gentler. Harvesting is an agricultural word. It describes taking something a field produces without asking the field’s permission, because a field can’t withhold consent — and a corporation, given the choice between a population that can refuse and a population that structurally cannot, will reliably prefer the second one. The word was accurate long before anyone used it as an accusation. It was simply, for years, the industry’s own quiet description of its business model.

The reforms that eventually came — heat treatment, viral inactivation, comprehensive screening, the near-total shift to voluntary unpaid donors across most of the developed world — didn’t arrive because the industry had a change of heart. They arrived because the invoices got too large to keep filing as an acceptable cost of doing business.

Here the irony has to drop entirely, because nothing about what comes next deserves a sentence built for effect. The people left holding the actual cost were never the memo writers. They were hemophiliacs who grew into adulthood, if they grew into adulthood at all, managing a chronic illness they didn’t choose and a diagnosis that, for years, arrived wrapped in the same stigma as the epidemic it resembled — patients who found themselves explaining, to employers and partners and sometimes their own extended families, that the disease came from medicine, not from anything they’d done, and finding that explanation didn’t always land. Families spent decades in compensation schemes that settled cases without ever requiring a company to admit, in writing, what its own memos had already admitted in private. A hundred thousand dollars, in some settlements, for a life permanently altered or a life that ended early — a number arrived at not because anyone calculated what the harm was actually worth, but because it was the number that let the filing get closed. Some of the people who spent decades demanding the public inquiry that finally delivered its verdict in 2024 did not live long enough to read it.

Three hundred and sixteen lots, one donor, one recall notice, filed and forgotten for forty years until someone went looking. That’s not a metaphor for how the system saw the people inside it. That’s the actual paperwork. The rest of us just finally learned to read it.

---

Further Reading:

• UK Infected Blood Inquiry — Final Report (2024) — The official 2024 findings, including documented failures in risk assessment, transparency, and patient protection spanning four decades.
• Krever Commission Final Report — Canada — Canada’s public inquiry into its contaminated blood system, tracing infections directly to U.S. prison and paid-donor plasma sources.
• “Nine Pints: A Journey Through the Money, Medicine, and Mysteries of Blood” — Rose George — The investigative account documenting the Cutter Biological internal memos quoted in this piece.